Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
BCR-ABL1-negative myeloproliferative neoplasms are burdened by a reduced life expectancy mostly due to an increased risk of thrombo-hemorrhagic events, fibrotic progression/leukemic evolution, and infectious complications. In these clonal myeloid malignancies, JAK2V617F is the main driver mutation,...
Enregistré dans:
Auteurs principaux: | Daniele Cattaneo, Alessandra Iurlo |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f0387f2811bc4960a7bb65e2a6fc62db |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Exploring redox vulnerabilities in JAK2V617F-positive cellular models
par: Keli Lima, et autres
Publié: (2021) -
Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
par: Lukas M. Braun, et autres
Publié: (2021) -
Ruxolitinib: a targeted treatment option for patients with polycythemia vera
par: Vaddi K, et autres
Publié: (2016) -
Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
par: Giulia Radi, et autres
Publié: (2021) -
Molecular basis of essential thrombocythaemia in humans and dogs – a review
par: Nicola Padzik, et autres
Publié: (2021)